HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

Benzinga · 2d ago
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 price target.